Roche acquires Inflazome; shareholders get €380M upfront payment

Inflazome has closed a share purchase agreement with Roche (OTCQX:RHHBY) in which Inflazome’s shareholders received an upfront payment of €380M, and are eligible to receive additional contingent payments based on the achievement of certain milestones. The company is a leader in the development of inflammasome inhibitors.

The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Activated NLRP3 acts as a ‘danger sensor’ in the body to release the pro-inflammatory cytokines IL-1β, IL-18 and induce uncontrolled, lytic cell death. These processes lead to chronic inflammation.

Inflazome has raised €55M in Venture Capital financing from leading investors Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund.

https://seekingalpha.com/news/3615556-roche-acquires-inflazome-shareholders-get-380m-upfront-payment